This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Deep Tissue Injury Treatment With MIST Therapy Versus Standard Care: REVERSE DTI Study

This study has been terminated.
(Lack of enrollment)
Information provided by (Responsible Party):
Celleration, Inc. Identifier:
First received: February 20, 2012
Last updated: January 6, 2015
Last verified: January 2015
The purpose of this study is to evaluate the effectiveness of MIST Therapy in conjunction with standard of care (SOC) compared to SOC alone in the prevention of deep tissue injury (DTI) progression to advanced stage pressure ulcers.

Condition Intervention
Wound of Skin Device: MIST Therapy Other: Standard of Care

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Multi-Center Study of the Effects of MIST Therapy on the Treatment of Deep Tissue Injury

Resource links provided by NLM:

Further study details as provided by Celleration, Inc.:

Primary Outcome Measures:
  • Effectiveness [ Time Frame: 14 days ]

    To compare between the treatment groups the effect of the assigned study treatment on the rate of progression of DTI to advanced stage pressure ulcer (Stage III or greater, continued DTI, or a pressure ulcer that is unable to be staged due to necrotic tissue).

    Stage I - Intact skin with non-blanchable redness of a localized area Stage II - Partial thickness loss of dermis Stage III - Full thickness loss, subcutaneous fat may be visible Stage IV - Full thickness tissue loss with exposed bone, tendon or muscle Unstageable - Full thickness tissue loss in which the base of the ulcer is covered by slough or eschar Continues deep tissue injury - purple or maroon localize area of discolored intact skin that may be mushy or boggy

Secondary Outcome Measures:
  • Change in Mean Wound Area [ Time Frame: 14 days ]
    Measured from randomization to last visit (14 days or at discharge from hospital)

Enrollment: 12
Study Start Date: February 2012
Study Completion Date: July 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: SOC - Standard of Care
Standard of care consists of pressure relief, creams, wound cleansing and dressings as needed
Other: Standard of Care
Standard of Care consists of pressure relief, wound cleansing and dressing as needed
Active Comparator: MIST Therapy with SOC
Standard of Care including pressure relief, wound cleansing, creams, and dressings as needed plus MIST Therapy daily for 5 days and then every other day for up to 7 more days
Device: MIST Therapy
FDA cleared non-contact ultrasound device. Delivers low frequency ultrasound via a fine saline to the wound area.
Other Name: MIST Therapy, MIST, Non-Contact Ultrasound

Detailed Description:

Enrolled subjects will be randomized to receive one of two treatment courses: a) MIST Therapy in conjunction with Standard of Care (MIST + SOC) (treatment group) or b) SOC only (control group).

A randomized subject will be required to undergo a Baseline Evaluation. The Baseline Evaluation. A digital photo will be taken of the wound.

The subject will receive the assigned study treatment. Each subject will receive SOC wound care and off-loading daily throughout the study. Subjects will be treated daily for 5 days and then every other day until discharged or up to 14 days post enrollment.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female subject of any race 18-90 years old.
  • Subject presents with an index DTI. This is defined by the National Pressure Ulcer Advisory Panel (NPUAP) as a purple or maroon localized area of discolored intact skin or blood-filled blister due to damage of underlying soft tissue from pressure and/or shear. The area may be preceded by tissue that is painful, firm, mushy, boggy, warmer or cooler as compared to adjacent tissue.
  • Subject's DTI has been discovered ≤ 72 hours after causative event
  • Causative event of DTI is identified.
  • Subject's index DTI is located on torso or body extremities.
  • Subject is currently admitted to the hospital.
  • Subject is able to be maneuvered into a position that is acceptable for MIST treatment.
  • Subject's DTI presents with no clinical signs of acute infection.
  • Subject or subject's legally authorized representative understands the nature of the procedures and provides written informed consent prior to study enrollment.

Exclusion Criteria:

  • Subject's primary wound is a Stage I, Stage II, Stage III or Stage IV pressure ulcer.
  • Subject's wound presents with a malignancy in the wound bed.
  • Subject has a history of pressure ulcer / DTI in same location.
  • Subject's DTI would require ultrasound near an electronic implant or prosthesis, e.g., near or over the heart, or over the thoracic area if the patient is using a cardiac pacemaker.
  • Female subjects that are pregnant or refuse to utilize adequate contraceptive methods and are of childbearing age during the trial.
  • Subject is terminally ill, defined as unable to survive beyond 14 days.
  • Subject is known to be suffering from a disorder or other situation that the subject or investigator feels would interfere with compliance or other study requirements.
  • Subject is currently enrolled or has been enrolled in the last 30 days in another device or drug trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01540981

United States, Nebraska
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
Sponsors and Collaborators
Celleration, Inc.
Principal Investigator: Joyce Black, PhD, RN University of Nebraska
  More Information

Responsible Party: Celleration, Inc. Identifier: NCT01540981     History of Changes
Other Study ID Numbers: CR-86034
Study First Received: February 20, 2012
Results First Received: October 6, 2014
Last Updated: January 6, 2015 processed this record on September 21, 2017